Regenxbio Overview
Latest ROE for Regenxbio: -273.72% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-273.72%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Regenxbio (RGNX) currently reports a ROE of -273.72%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Regenxbio's ROE history and peer comparisons.
Regenxbio's ROE of -273.72% is lower than the Healthcare sector average of 21.28%. That is roughly 1386.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Regenxbio's current -273.72% should be judged against Healthcare norms (sector average: 21.28%) and against RGNX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -273.72%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Regenxbio, and consider following RGNX for alerts when major investors trade the stock.
Regenxbio is classified in the Healthcare sector. On ROE, it currently shows -273.72% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGNX with unrelated industries.
